BRIM Biotechnology, Inc. (6885.TWO)

TWD 37.6

(0.0%)

Market Cap (In TWD)

4.93 Billion

Revenue (In TWD)

90 Thousand

Net Income (In TWD)

-688.02 Million

Avg. Volume

728.77 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
24.6-73.6
PE
-
EPS
-
Beta Value
1.203
ISIN
TW0006885007
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Wenqi Xu Ph.D.
Employee Count
-
Website
https://www.brimbiotech.com
Ipo Date
2022-06-24
Details
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.